0,05. Доказательная медицина от магии до поисков бессмертия

Ong E. K., Glantz S. A. Constructing “sound science” and “good epidemiology”: Tobacco, lawyers, and public relations firms // American journal of public health. 2001. November. Vol. 91. № 11. P. 1749–1757.

Bero L. A. Tobacco industry manipulation of research // Public Health Reports. 2005. March/April. Vol. 120. № 2. P. 200–208.

Velicer C., Helen G., Glantz S. A. Tobacco papers and tobacco industry ties in regulatory toxicology and pharmacology // Journal of public health policy. 2018. February. Vol. 39. № 1. P. 34–48.

Boffetta P., Couto E., Wichmann J., Ferrari P., Trichopoulos D. et al. Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) // Journal of the National Cancer Institute. 2010. April 21. Vol. 102. № 8. P. 529–537.

Siontis G. C. M., Ioannidis J. P. A. Risk factors and interventions with statistically significant tiny effects // International Journal of Epidemiology. 2011. October. Vol. 40. № 5. P. 1292–1307.

De Boer M., Van Leeuwen F. E., Hauptmann M., Overbeek L. et al Breast implants and the risk of anaplastic large-cell lymphoma in the breast // JAMA Oncology. 2018. Vol. 4. № 3. P. 335–341.

Doren E. L., Miranda R. N., Selber J. C., Garvey P. B., Liu J., Medeiros L. J. et al. U. S. epidemiology of breast implant-associated anaplastic large cell lymphoma // Plastic and reconstructive surgery. 2017. May. Vol. 139. № 5. P. 1042–1050.

Bouvard V., Loomis D., Guyton K. Z., Grosse Y., Ghissassi F. et al. Carcinogenicity of consumption of red and processed meat // Lancet Oncology. 2015. December. Vol. 16. P. 1599–1600.

Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund / American Institute for Cancer Research. Washington DC: AICR, 2007.

Chan D. S., Lau R., Aune D., Vieira R., Greenwood D. C., Kampman E., Norat T. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies // PLoS One. 2011. Vol. 6. № 6, e20456.

Truswell A. S. Problems with red meat in the WCRF2 // American Journal of Clinical Nutrition. 2009. Vol. 89. № 4. P. 1274–1275.

Wei E. K., Giovannucci E., Wu K., Rosner B., Fuchs C. S., Willett W. C., Colditz G. A. Comparison of risk factors for colon and rectal cancer // International Journal of Cance. 2004. January 20. Vol. 108. № 3. P. 433–442.

Tai V., Grey A., Bolland M. J. Results of observational studies: analysis of findings from the Nurses’ Health Study // PLoS One. 2014. Vol. 9. № 10, e110403.

Часть пятая

Overington J. P., Al-Lazikani B., Hopkins A. L. How many drug targets are there? // Nature reviews. Drug discovery. 2006. December. Vol. 5. № 12. P. 993–996.

Kaplan R. M., Irvin V. L. Likelihood of null effects of large NHLBI clinical trials has increased over time // Plos Оne. 2015. August 5. Vol. 10. № 8, e0132382.

Chalmers I., Glasziou P. Avoidable waste in the production and reporting of research evidence // Lancet. 2009. Vol. 374. № 9683. P. 86–89.

Prinz F., Schlange T., Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? // Nature Reviews Drug Discovery. 2011. Vol. 10. № 9. P. 712–713.

Begley C. G. Six red flags for suspect work // Nature. 2013. May 23. Vol. 497. № 7450. P. 433–434.

Begley C. G., Ellis L. M. Raise standards for preclinical cancer research // Nature. 2012. March 29. Vol. 483. P. 531–533.

Plourde G. Validation of surrogate endpoints for clinical trials // Journal of Pharmacology & Clinical Research. 2018. Vol. 5. № 2, 555657.